Showing 81-90 of 9661 results for "".
- New Imaging Approach Shows High Agreement in Mohs Margin Assessment: Studyhttps://practicaldermatology.com/news/2-new-imaging-approach-shows-high-agreement-in-mohs-margin-assessment/2488673/A recent Modern Pathology study reported found that ex vivo fluorescence confocal microscopy (EVFCM) achieved high overall diagnostic accuracy in assessing surgical margins during Mohs surgery for nonmelanoma skin cancer (NMSC). EVFCM Shows Strong Agreement With Histopathology i
- Switching From Dupilumab to Upadacitinib Associated With No Skin Flares in Atopic Dermatitis Analysishttps://practicaldermatology.com/news/switching-from-dupilumab-to-upadacitinib-associated-with-few-flares-in-atopic-dermatitis-analysis/2488672/Patients with moderate-to-severe atopic dermatitis (AD) who switched from dupilumab to upadacitinib monotherapy following inadequate treatment response experienced no observed skin lesion flares and infrequent itch flares over 16 weeks, according to a post hoc analysis pres
- Consensus IDs Gaps in Atopic Dermatitis Skin Modelshttps://practicaldermatology.com/news/consensus-ids-gaps-in-atopic-dermatitis-skin-models/2488670/A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD), identifying opportunities to improve preclinical research and reduce reliance on animal models. R
- Upadacitinib Shows Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-earlier-skin-barrier-restoration-than-dupilumab-in-atopic-dermatitis/2488646/A biomarker analysis from the head-to-head Level Up study found that upadacitinib produced early molecular and histologic changes consistent with restoration of the skin barrier in adults with moderate-to-severe atopic dermatitis (AD), with broader changes than dupilumab in the study’s optional b
- FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographismhttps://practicaldermatology.com/news/fda-approves-remibrutinib-as-first-treatment-for-symptomatic-dermographism/2488642/The FDA has approved Rhapsido (remibrutinib; Novartis) for adults with symptomatic dermographism (SD) whose disease is inadequately controlled with H1 antihistamines, according to an October 7 announcement from Novartis. The approval makes remibrutinib the first FDA-approved treatment spec
- Earlier-Onset Atopic Dermatitis Linked With Cow’s Milk Sensitization: Studyhttps://practicaldermatology.com/news/earlier-onset-atopic-dermatitis-linked-with-cows-milk-sensitization-study/2488641/Egg and cow’s milk were the most common food allergens identified by skin prick testing among infants with atopic dermatitis (AD) in a 17-year retrospective study from Iran, although the investigators cautioned that testing alone cannot establish clinically confirmed food allergy. Publishe
- Emblation Names Four Medical Affairs Advisors for SwiftProhttps://practicaldermatology.com/news/emblation-names-four-medical-affairs-advisors-for-swiftpro/2488631/Emblation has appointed four clinicians and podiatry experts as Medical Affairs Advisors to support clinical education initiatives surrounding its SwiftPro microwave therapy system, which the company said recently received US Food and Drug Administration (FDA) 510(k) cleara
- Acrotech Brings Difamilast 1% Ointment for Atopic Dermatitis to UShttps://practicaldermatology.com/news/acrotech-brings-difamilast-1-ointment-for-atopic-dermatitis-to-us/2488630/Acrotech Biopharma Inc. announced the United States launch of ADQUEY (difamilast 1%) ointment, a nonsteroidal topical treatment for mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 years and older. Difamilast was originally developed by Otsuka Pharmaceutical
- Marie Claire Recognizes ZORYVE for Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/marie-claire-recognizes-zoryve-for-atopic-dermatitis-treatment/2488632/Arcutis Biotherapeutics announced that roflumilast cream 0.15% (ZORYVE) received Marie Claire’s inaugural 2026 Best Prescription Skin Solution Award, a new category recognizing innovation in prescription dermatologic treatments. The award recognizes ZORYVE f
- Environmental Exposures, Skin Barrier Care Take Focus in Pediatric AD Consensushttps://practicaldermatology.com/news/environmental-exposures-skin-barrier-care-take-focus-in-pediatric-ad-consensus/2488624/Environmental exposures early in childhood that affect the skin barrier may contribute to the development of atopic dermatitis, and impact its severity, according to a new expert consensus published in the Journal of Drugs in Dermatology. The SAIGE III report examined current evid